UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells

Frontiers in immunology, 2024, Vol.15, p.1346686-1346686

2024

Volltextzugriff (PDF)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

ACS medicinal chemistry letters, 2017-05, Vol.8 (5), p.486-491

2017

Volltextzugriff (PDF)

Abstract 1882 Integrin α6β4 Regulates Tryptophan Metabolism through the Kynurenine Pathway in Triple Negative Breast Cancer

The Journal of biological chemistry, 2024-03, Vol.300 (3), p.106468, Article 106468

2024

Volltextzugriff (PDF)

Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?

Annual review of cancer biology, 2020-03, Vol.4 (1), p.241-256

2020

Volltextzugriff (PDF)

Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors

European journal of medicinal chemistry, 2023-03, Vol.250, p.115217-115217, Article 115217

2023

Volltextzugriff (PDF)

IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth

Biomedicine & pharmacotherapy, 2024-10, Vol.179, p.117412, Article 117412

2024

Volltextzugriff (PDF)

FOXM1 derived from Triple negative breast cancer exosomes promotes cancer progression by activating IDO1 transcription in macrophages to suppress ferroptosis and induce M2 polarization of Tumor-associated macrophages

Genes & Genetic Systems, 2024, pp.24-00079

2024

Volltextzugriff (PDF)

IDO1-mediated catabolism of tryptophan in gastric tumors: Its potential role in the axis of histopathology, differentiation and metastasis

Pathology, research and practice, 2024-11, Vol.263, p.155655, Article 155655

2024

Volltextzugriff (PDF)

Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity

Journal of enzyme inhibition and medicinal chemistry, 2019-01, Vol.34 (1), p.1481-1488

2019

Volltextzugriff (PDF)

Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer

Cancer pathogenesis and therapy, 2024-10, Vol.2 (4), p.246-255

Sarangi, Pratyasha

2024

Volltextzugriff (PDF)

The Kynurenine Pathway-New Linkage between Innate and Adaptive Immunity in Autoimmune Endocrinopathies

International journal of molecular sciences, 2021-09, Vol.22 (18), p.9879

2021

Volltextzugriff (PDF)

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Nature Medicine, 2020-05, Vol.26 (5), p.681-687

2020

Volltextzugriff (PDF)

Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase

Bioorganic & medicinal chemistry letters, 2020-06, Vol.30 (11), p.127159, Article 127159

2020

Volltextzugriff (PDF)

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

Trends in pharmacological sciences (Regular ed.), 2018-03, Vol.39 (3), p.307-325

2018

Volltextzugriff (PDF)

Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy

European journal of medicinal chemistry, 2022-08, Vol.238, p.114524-114524, Article 114524

2022

Volltextzugriff (PDF)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers

Frontiers in oncology, 2018-10, Vol.8, p.423-423

2018

Volltextzugriff (PDF)

Coordination Polymer‐Coated CaCO3 Reinforces Radiotherapy by Reprogramming the Immunosuppressive Metabolic Microenvironment

Advanced materials (Weinheim), 2022-01, Vol.34 (3), p.e2106520-n/a

2022

Volltextzugriff (PDF)

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy

European journal of medicinal chemistry, 2022-01, Vol.227, p.113967-113967, Article 113967

2022

Volltextzugriff (PDF)

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Journal of hematology and oncology, 2021-04, Vol.14 (1), p.68-68, Article 68

2021

Volltextzugriff (PDF)

IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10

Pharmacological research, 2022-03, Vol.177, p.106132-106132, Article 106132

2022

Volltextzugriff (PDF)

The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma

Oncoimmunology, 2023-12, Vol.12 (1), p.2170095-2170095

2023

Volltextzugriff (PDF)

Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO

Biochemical pharmacology, 2019-10, Vol.168, p.214-223

2019

Volltextzugriff (PDF)

Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form

Proceedings of the National Academy of Sciences - PNAS, 2018-03, Vol.115 (13), p.3249-3254

2018

Volltextzugriff (PDF)

1 – 25 von 448

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(431)
Mit Volltextzugriff
(424)

Publikationsform

Sprache

Englisch
(448)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(406)
Life Sciences & Biomedicine
(385)
Ido1
(312)
Humans
(167)
Indoleamine-Pyrrole 2,3,-Dioxygenase - Metabolism
(120)
Pharmacology & Pharmacy
(116)
Animals
(111)
Immunology
(94)
Oncology
(90)
Tryptophan
(90)
Immunotherapy
(83)
Chemistry, Medicinal
(75)
Mice
(75)
Female
(62)
Biochemistry & Molecular Biology
(61)
Indoleamine-Pyrrole 2,3,-Dioxygenase - Genetics
(57)
Indoleamine-Pyrrole 2,3,-Dioxygenase - Antagonists & Inhibitors
(54)
Kynurenine
(52)
Tumors
(51)
Cancer
(49)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

Abstract 1882 Integrin α6β4 Regulates Tryptophan Metabolism through the Kynurenine Pathway in Triple Negative Breast Cancer

Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?

Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors

IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth

FOXM1 derived from Triple negative breast cancer exosomes promotes cancer progression by activating IDO1 transcription in macrophages to suppress ferroptosis and induce M2 polarization of Tumor-associated macrophages

IDO1-mediated catabolism of tryptophan in gastric tumors: Its potential role in the axis of histopathology, differentiation and metastasis

Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity

Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer

Class IA PI3Ks regulate subcellular and functional dynamics of IDO1

The Kynurenine Pathway-New Linkage between Innate and Adaptive Immunity in Autoimmune Endocrinopathies

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication

Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers

Coordination Polymer‐Coated CaCO3 Reinforces Radiotherapy by Reprogramming the Immunosuppressive Metabolic Microenvironment

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10

The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma

Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO

Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form

Suchergebnisse filtern